Bridging the treatment
gap of endometriosis.
Local treatment. Global impact. A novel sustained-release platform that treats disease at the source, without systemic side effects.
The problem
A chronic, under-treated disease.
Endometriosis is a chronic inflammatory disease in which uterine-like cells grow outside the uterus, predominantly in the peritoneal cavity, forming estrogen-driven lesions that cause pain, infertility, and organ damage.
women worldwide live with endometriosis
of reproductive-age women are affected
annual burden in the United States
The treatment gap
Today's options leave most patients underserved.
No approved treatment combines disease modification, tolerability, and patient convenience. That is the gap Endospot fills.
Our approach
Three principles, one platform.
Efficacy
Targets estrogen-producing enzymes directly at the lesion site, delivering disease modification at the source.
Safety
Peritoneal retention prevents systemic absorption, eliminating menopausal side effects entirely.
Patient-centered
A single administration delivers three months of continuous low-dose release.